Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma (PDL)
Primary Purpose
Telangiectasia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
pulsed dye laser
Sponsored by
About this trial
This is an interventional treatment trial for Telangiectasia
Eligibility Criteria
Inclusion Criteria:
- patient followed in dermatology and/or internal medicine at the University Hospital of Caen for systemic scleroderma
- patient with telangiectasias related to scleroderma
- patient with an aesthetic prejudice
Exclusion Criteria:
- Patient with previous laser treatment for facial telangiectasias.
- Tanned, irritated or traumatized facial skin
- Patient not affiliated to the Social Security system
- Pregnancy
Sites / Locations
- Chu Caen Normandie
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
four pulsed dye laser sessions were administered every eight weeks in the 21 patients
Arm Description
Outcomes
Primary Outcome Measures
Evaluation of the decrease in the number of telangiectasia
Secondary Outcome Measures
Assessment of quality of life after pulsed dye laser treatment using the SKINDEX questionnaire
Full Information
NCT ID
NCT05036200
First Posted
July 19, 2021
Last Updated
August 30, 2021
Sponsor
University Hospital, Caen
1. Study Identification
Unique Protocol Identification Number
NCT05036200
Brief Title
Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma
Acronym
PDL
Official Title
Efficacy, Tolerance and Acceptability of Pulsed Dye Laser on Telangiectasias of the Face and Neckline in Systemic Scleroderma: a Prospective Single-center Open-label Study of 21 Patients
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
August 1, 2019 (Actual)
Primary Completion Date
September 1, 2019 (Actual)
Study Completion Date
July 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Caen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This single-center, prospective, open-label, quasi-experimental, intra-individual comparative study will include a consecutive cohort of 21 patients with diffuse or limited, minimally active scleroderma with 3 to 30 years of evolution.
Patients will have 4 sessions of pulsed dye laser 595 nm spaced 8 weeks apart. The final quadruple evaluation by several evaluators will be 2 months after the last session, on the following criteria: evolution of the number of telangiectasia; subjective improvement score (LINKERT scale); impact on quality of life (SKINDEX score); visual analog pain scale (VAS); adverse events (AEs), including discontinuation of treatment due to post-session purpura (AT-PPS); patient satisfaction (yes or no).
Detailed Description
Primary Objective:
To evaluate the efficacy of pulsed dye laser treatment on facial and neckline telangiectasias in systemic scleroderma by comparing the mean number of telangiectasias.
Secondary Objectives:
Evaluation of the aesthetic efficacy by the patient, observer and adjudication committee Evaluation of the impact on the quality of life after treatment (skindex) Evaluation of treatment tolerance in terms of pain (VAS) and adverse events (purpura, oozing, hyperpigmentation, hospitalization)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Telangiectasia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
four pulsed dye laser sessions were administered every eight weeks in the 21 patients
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
pulsed dye laser
Intervention Description
four pulsed dye laser sessions were administered every eight weeks in the 21 patients
Primary Outcome Measure Information:
Title
Evaluation of the decrease in the number of telangiectasia
Time Frame
baseline and two months after last intervention
Secondary Outcome Measure Information:
Title
Assessment of quality of life after pulsed dye laser treatment using the SKINDEX questionnaire
Time Frame
baseline and two months after last intervention
Other Pre-specified Outcome Measures:
Title
evaluation of the aesthetic improvement with an improvement score scored using a LIKERT scale from -1 to +2: from -1= worse; 0= unchanged ; +1= improved ; +2= much improved
Time Frame
baseline and two months after last intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient followed in dermatology and/or internal medicine at the University Hospital of Caen for systemic scleroderma
patient with telangiectasias related to scleroderma
patient with an aesthetic prejudice
Exclusion Criteria:
Patient with previous laser treatment for facial telangiectasias.
Tanned, irritated or traumatized facial skin
Patient not affiliated to the Social Security system
Pregnancy
Facility Information:
Facility Name
Chu Caen Normandie
City
Caen
State/Province
Normandie
ZIP/Postal Code
14000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
23899131
Citation
Mayo TT, Khan F, Hunt C, Fleming K, Markus R. Comparative study on bruise reduction treatments after bruise induction using the pulsed dye laser. Dermatol Surg. 2013 Oct;39(10):1459-64. doi: 10.1111/dsu.12293. Epub 2013 Jul 30.
Results Reference
background
PubMed Identifier
25797836
Citation
Yalcinkaya Y, Pehlivan O, Omma A, Alpay N, Erer B, Kamali S, Ocal L, Inanc M. The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S92-7. Epub 2015 Mar 23.
Results Reference
background
Learn more about this trial
Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma
We'll reach out to this number within 24 hrs